Analysts expect ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to post earnings per share (EPS) of ($0.69) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for ACADIA Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.72) and the highest estimate coming in at ($0.66). ACADIA Pharmaceuticals reported earnings per share of ($0.61) during the same quarter last year, which would suggest a negative year-over-year growth rate of 13.1%. The firm is scheduled to report its next earnings report on Monday, November 6th.

On average, analysts expect that ACADIA Pharmaceuticals will report full year earnings of ($2.82) per share for the current year, with EPS estimates ranging from ($2.91) to ($2.70). For the next financial year, analysts expect that the firm will post earnings of ($2.07) per share, with EPS estimates ranging from ($2.47) to ($1.54). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that cover ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.72) by $0.17. The firm had revenue of $30.50 million during the quarter, compared to analysts’ expectations of $20.02 million. ACADIA Pharmaceuticals had a negative return on equity of 59.00% and a negative net margin of 485.14%. ACADIA Pharmaceuticals’s quarterly revenue was up 30400.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.63) EPS.

Several analysts have recently weighed in on the company. Piper Jaffray Companies set a $54.00 price objective on ACADIA Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday. ValuEngine raised ACADIA Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday. Cowen and Company reissued an “outperform” rating and set a $46.00 price objective (up previously from $42.00) on shares of ACADIA Pharmaceuticals in a report on Thursday. HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of ACADIA Pharmaceuticals in a report on Wednesday. Finally, BidaskClub raised ACADIA Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, July 24th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and ten have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $43.15.

In related news, EVP Glenn Baity sold 38,097 shares of the business’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $30.00, for a total value of $1,142,910.00. Following the sale, the executive vice president now owns 109,253 shares of the company’s stock, valued at approximately $3,277,590. The sale was disclosed in a legal filing with the SEC, which is available through this link. 22.25% of the stock is owned by insiders.

Hedge funds have recently made changes to their positions in the stock. BlackRock Inc. raised its stake in shares of ACADIA Pharmaceuticals by 5,422.8% in the first quarter. BlackRock Inc. now owns 5,433,209 shares of the biopharmaceutical company’s stock valued at $186,791,000 after buying an additional 5,334,832 shares in the last quarter. Elliott Management Corp bought a new stake in shares of ACADIA Pharmaceuticals during the first quarter valued at approximately $26,726,000. Point72 Asset Management L.P. raised its stake in shares of ACADIA Pharmaceuticals by 57.6% in the first quarter. Point72 Asset Management L.P. now owns 1,931,200 shares of the biopharmaceutical company’s stock valued at $66,395,000 after buying an additional 706,200 shares in the last quarter. First Trust Advisors LP raised its stake in shares of ACADIA Pharmaceuticals by 60.8% in the second quarter. First Trust Advisors LP now owns 1,402,029 shares of the biopharmaceutical company’s stock valued at $39,103,000 after buying an additional 530,103 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its stake in shares of ACADIA Pharmaceuticals by 134.7% in the first quarter. Ameriprise Financial Inc. now owns 882,722 shares of the biopharmaceutical company’s stock valued at $30,329,000 after buying an additional 506,605 shares in the last quarter. 97.34% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This story was first published by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.dailypolitical.com/2017/08/10/zacks-brokerages-expect-acadia-pharmaceuticals-inc-acad-will-announce-earnings-of-0-69-per-share.html.

ACADIA Pharmaceuticals (ACAD) traded down 8.97% during trading on Thursday, reaching $30.23. The company’s stock had a trading volume of 3,469,969 shares. ACADIA Pharmaceuticals has a 52-week low of $20.68 and a 52-week high of $40.83. The firm’s market capitalization is $3.69 billion. The stock’s 50-day moving average is $29.25 and its 200 day moving average is $32.03.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Get a free copy of the Zacks research report on ACADIA Pharmaceuticals (ACAD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.